关于阿瓦斯汀等药物“超适应症”使用的一些伦理考量。
Some ethical considerations for the "off-label" use of drugs such as Avastin.
作者信息
Wong D, Kyle G
机构信息
St Paul's Eye Unit, Royal Liverpool University Trust Hospital, Liverpool, UK.
出版信息
Br J Ophthalmol. 2006 Oct;90(10):1218-9. doi: 10.1136/bjo.2006.102426.
Abstract
Is off‐label use of drugs legal?
摘要
药物的非标签使用是否合法？
相似文献
1
Some ethical considerations for the "off-label" use of drugs such as Avastin.
Br J Ophthalmol. 2006 Oct;90(10):1218-9. doi: 10.1136/bjo.2006.102426.
2
Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002.
3
Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
Retina. 2007 Nov-Dec;27(9):1163-5. doi: 10.1097/IAE.0b013e31815e9322.
4
Avastin versus Lucentis: ethical issues.
Retina. 2008 Jul-Aug;28(7):1024-5; author reply 1025. doi: 10.1097/IAE.0b013e318176de5f.
5
CATT: Into the eye of a tiger.
Br J Ophthalmol. 2011 Jun;95(6):761. doi: 10.1136/bjophthalmol-2011-300406.
6
Treatments for macular degeneration: summarising evidence using network meta-analysis.
Br J Ophthalmol. 2011 Oct;95(10):1476-7. doi: 10.1136/bjophthalmol-2011-300316. Epub 2011 Jun 16.
7
Bevacizumab: a new way of doing business?
Eye (Lond). 2006 Sep;20(9):985-7. doi: 10.1038/sj.eye.6702501. Epub 2006 Jul 21.
8
Intravitreal avastin: the low cost alternative to lucentis?
Am J Ophthalmol. 2006 Jul;142(1):141-3. doi: 10.1016/j.ajo.2006.03.036.
9
Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?
Acta Ophthalmol Scand. 2007 Feb;85(1):2-4. doi: 10.1111/j.1600-0420.2006.00869.x.
10
Avastin and new treatments for AMD: where are we?
Retina. 2006 Oct;26(8):853-8. doi: 10.1097/01.iae.0000244722.35073.7c.
引用本文的文献
1
Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?
Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002.
2
Off-label use of medicines: medical research and medical practice.
Indian J Ophthalmol. 2007 Nov-Dec;55(6):411-2. doi: 10.4103/0301-4738.36472.
本文引用的文献
1
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Retina. 2006 Apr;26(4):383-90. doi: 10.1097/01.iae.0000238561.99283.0e.
2
Intravitreal bevacizumab in a patient with neovascular glaucoma.
Ophthalmic Surg Lasers Imaging. 2006 Mar-Apr;37(2):144-6.
3
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
Retina. 2006 Mar;26(3):352-4. doi: 10.1097/00006982-200603000-00016.
4
Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.
Retina. 2006 Mar;26(3):279-84. doi: 10.1097/00006982-200603000-00005.
5
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
Retina. 2006 Mar;26(3):275-8. doi: 10.1097/00006982-200603000-00004.
6
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Ophthalmology. 2006 Mar;113(3):363-372.e5. doi: 10.1016/j.ophtha.2005.11.019. Epub 2006 Feb 3.
7
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.
Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):336-9.
8
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.
9
Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment?
Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):270-1.
10
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
Arch Ophthalmol. 2003 Sep;121(9):1253-68. doi: 10.1001/archopht.121.9.1253.
Zotero 插件